AbbVie Competitors and Similar CompaniesClear all

Astellas Pharma's competitors and similar companies include Gilead Sciences, Immunomedics, Sanofi, Amgen, Bristol Myers Squibb, Abbott, Merck Group, GSK, Novartis, Roche and Johnson & Johnson.
Astellas Pharma
Astellas Pharma
Astellas Pharma (アステラス製薬株式会社) is a pharmaceutical company focused on the development of drugs and medical solutions.
Gilead Sciences
Gilead Sciences
Gilead Sciences is a research-based biopharmaceutical company focused on the discovery, development, and commercialization of medicines.
Immunomedics
Immunomedics
Immunomedics is a developer of monoclonal antibody-based products for the targeted treatment of cancer.
Sanofi
Sanofi
Sanofi is a global healthcare company engaged in the research, development, manufacture, and marketing of therapeutic solutions.
Amgen
Amgen
Amgen (formerly known as Applied Molecular Genetics) is a biotechnology company that discovers, develops, manufactures, and delivers human therapeutics.
Bristol Myers Squibb
Bristol Myers Squibb
Bristol-Myers Squibb (BMS) is a company engaged in the discovery, development, licensing, manufacturing, marketing, and distribution of biopharmaceutical products.
Abbott
Abbott
Abbott Laboratories is a company that develops, manufactures, and sells healthcare products.
Merck Group
Merck Group
Merck Group is a science and technology company.
GSK
GSK
GSK (GlaxoSmithKline) is a science-led healthcare company that researches, develops, and manufactures pharmaceutical medicines, vaccines, and consumer healthcare products.
Novartis
Novartis
Novartis is a company that researches, develops, manufactures, and markets healthcare products.
Roche
Roche
Roche Holding is a biotech company that provides in-vitro diagnostics and supplies solutions across various disease areas.
Johnson & Johnson
Johnson & Johnson
Johnson & Johnson (J&J) is a company that engages in the research and development, manufacture, and sale of a range of products in the healthcare field.
Founding Date
Founding Date
1923
Founding Date
1987
Founding Date
1982
Founding Date
2004
Founding Date
1980
Founding Date
1887
Founding Date
1894
Founding Date
1668
Founding Date
2000
Founding Date
1996
Founding Date
1896
Founding Date
1886
Type
Type
Public
Type
Public
Type
Subsidiary
Type
Public
Type
Public
Type
Public
Type
Public
Type
Public
Type
Public
Type
Public
Type
Public
Type
Public
Tags
Locations
Locations
Tokyo, JP HQ
Macquarie Park, AU
Wien, AT
Vilvoorde, BE
São Paulo, BR
Markham, CA
Beijing, CN
see more
Locations
Foster City, US HQ
Buenos Aires, AR
Melbourne, AU
Wien, AT
Machelen, BE
São Paulo, BR
Edmonton, CA
see more
Locations
Morris Plains, US HQ
Locations
Paris, FR HQ
Hydra, DZ
Macquarie Park, AU
Wien, AT
Dhaka, BD
Brussel, BE
Geel, BE
see more
Locations
Thousand Oaks, US HQ
Hydra, DZ
Vicente López, AR
Sydney, AU
Wien, AT
Diegem, BE
Santo Amaro, BR
see more
Locations
Princeton, US HQ
Mulgrave, AU
Pinewood, AU
Wien, AT
Braine L'alleud, BE
Bruxelles, BE
São Paulo, BR
see more
Locations
Abbott Park, US HQ
Tiranë, AL
Buenos Aires, AR
Yerevan, AM
Doncaster, AU
East Brisbane, AU
Macquarie Park, AU
see more
Locations
Darmstadt, DE HQ
Buenos Aires, AR
Bayswater, AU
Macquarie Park, AU
Wien, AT
Hoeilaart, BE
Rio De Janeiro, BR
see more
Locations
Brentford, GB HQ
Boumerdes, DZ
San Fernando, AR
Abbotsford, AU
Boronia, AU
Ermington, AU
Wien, AT
see more
Locations
Basel, CH HQ
Tirana, AL
Buenos Aires, AR
Macquarie Park, AU
Kundl, AT
Unterlangkampfen, AT
Wien, AT
see more
Locations
Basel, CH HQ
Hydra, DZ
Ricardo Rojas, AR
North Ryde, AU
Sydney, AU
Wien, AT
Dhaka, BD
see more
Locations
New Brunswick, US HQ
Buenos Aires, AR
Sydney, AU
Ultimo, AU
Wien, AT
Minsk, BY
Beerse, BE
see more
Employees
Employees
14,484
Employees
18,0006% increase
Employees
1073% decrease
Employees
86,0886% decrease
Employees
25,200
Employees
34,1001% decrease
Employees
115,0002% increase
Employees
62,9081% decrease
Employees
70,2121% increase
Employees
76,057
Employees
103,605
Employees
152,7008% increase
Valuation ($)
Valuation ($)
16.8 b
Valuation ($)
82.5 b
Valuation ($)
N/A
Valuation ($)
N/A
Valuation ($)
142.3 b
Valuation ($)
103.1 b
Valuation ($)
197.7 b
Valuation ($)
70.4 b
Valuation ($)
N/A
Valuation ($)
N/A
Valuation ($)
N/A
Valuation ($)
389.7 b
Twitter followers
Twitter followers
50.4 k
Twitter followers
73.8 k
Twitter followers
568
Twitter followers
151.6 k
Twitter followers
123.5 k
Twitter followers
156.9 k
Twitter followers
123.5 k
Twitter followers
24.9 k
Twitter followers
242.6 k
Twitter followers
301.8 k
Twitter followers
247.2 k
Twitter followers
250 k
Number of tweets (last 30 days)
Number of tweets (last 30 days)
25
Number of tweets (last 30 days)
22
Number of tweets (last 30 days)
N/A
Number of tweets (last 30 days)
35
Number of tweets (last 30 days)
91
Number of tweets (last 30 days)
16
Number of tweets (last 30 days)
57
Number of tweets (last 30 days)
51
Number of tweets (last 30 days)
50
Number of tweets (last 30 days)
4
Number of tweets (last 30 days)
33
Number of tweets (last 30 days)
8
Average likes per tweet (last 30 days)
Average likes per tweet (last 30 days)
5.8
Average likes per tweet (last 30 days)
48.1
Average likes per tweet (last 30 days)
N/A
Average likes per tweet (last 30 days)
15.6
Average likes per tweet (last 30 days)
4.8
Average likes per tweet (last 30 days)
6.4
Average likes per tweet (last 30 days)
4.4
Average likes per tweet (last 30 days)
5.9
Average likes per tweet (last 30 days)
8.2
Average likes per tweet (last 30 days)
8.5
Average likes per tweet (last 30 days)
9.8
Average likes per tweet (last 30 days)
13.9
Percentage of tweets with engagement (last 30 days)
Percentage of tweets with engagement (last 30 days)
96%
Percentage of tweets with engagement (last 30 days)
100%
Percentage of tweets with engagement (last 30 days)
N/A
Percentage of tweets with engagement (last 30 days)
91.43%
Percentage of tweets with engagement (last 30 days)
97.8%
Percentage of tweets with engagement (last 30 days)
93.75%
Percentage of tweets with engagement (last 30 days)
24.56%
Percentage of tweets with engagement (last 30 days)
96.08%
Percentage of tweets with engagement (last 30 days)
82%
Percentage of tweets with engagement (last 30 days)
75%
Percentage of tweets with engagement (last 30 days)
84.85%
Percentage of tweets with engagement (last 30 days)
75%

Financial

Revenue (est.)
Revenue (est.)
¥1.5t (FY, 2023)
Revenue (est.)
$27.1b (FY, 2023)
Revenue (est.)
$295k (FY, 2019)
Revenue (est.)
€43.1b (FY, 2023)
Revenue (est.)
$28.2b (FY, 2023)
Revenue (est.)
$45b (FY, 2023)
Revenue (est.)
$40.1b (FY, 2023)
Revenue (est.)
€21b (FY, 2023)
Revenue (est.)
£30.3b (FY, 2023)
Revenue (est.)
$54.1b (FY, 2023)
Revenue (est.)
CHF58.7b (FY, 2023)
Revenue (est.)
$85.2b (FY, 2023)
Cost of goods
Cost of goods
¥182.6b (FY, 2023)
Cost of goods
$6.5b (FY, 2023)
Cost of goods
N/A
Cost of goods
€12.5b (FY, 2023)
Cost of goods
$8.5b (FY, 2023)
Cost of goods
$10.7b (FY, 2023)
Cost of goods
$18b (FY, 2023)
Cost of goods
€7.3b (FY, 2023)
Cost of goods
£5.8b (FY, 2023)
Cost of goods
$8.2b (FY, 2023)
Cost of goods
CHF12.4b (FY, 2023)
Cost of goods
$26.6b (FY, 2023)
Gross profit
Gross profit
¥1.3t (FY, 2023)
Gross profit
$20.6b (FY, 2023)
Gross profit
$295k (FY, 2019)
Gross profit
€34.5b (FY, 2023)
Gross profit
$19.7b (FY, 2023)
Gross profit
$34.3b (FY, 2023)
Gross profit
$22.1b (FY, 2023)
Gross profit
€13.9b (FY, 2023)
Gross profit
£25.7b (FY, 2023)
Gross profit
$47.7b (FY, 2023)
Gross profit
CHF48.5b (FY, 2023)
Gross profit
$58.6b (FY, 2023)
Net income
Net income
¥98.7b (FY, 2023)
Net income
$5.6b (FY, 2023)
Net income
($357.3m) (FY, 2019)
Net income
€5.6b (FY, 2023)
Net income
$6.7b (FY, 2023)
Net income
$8b (FY, 2023)
Net income
$5.7b (FY, 2023)
Net income
€2.8b (FY, 2023)
Net income
£5.3b (FY, 2023)
Net income
$9b (FY, 2023)
Net income
CHF12.4b (FY, 2023)
Net income
$35.2b (FY, 2023)

Operating

Countries
Countries
N/A
Countries
35 (FY, 2021)
Countries
N/A
Countries
N/A
Countries
100 (FY, 2020)
Countries
N/A
Countries
N/A
Countries
66 (FY, 2021)
Countries
92 (FY, 2021)
Countries
N/A
Countries
N/A
Countries
N/A
Patents (US)
Patents (US)
N/A
Patents (US)
N/A
Patents (US)
405 (Sep, 2022)
Patents (US)
N/A
Patents (US)
31 (FY, 2020)
Patents (US)
N/A
Patents (US)
N/A
Patents (US)
N/A
Patents (US)
N/A
Patents (US)
N/A
Patents (US)
N/A
Patents (US)
N/A
Patients
Patients
N/A
Patients
N/A
Patients
N/A
Patients
N/A
Patients
N/A
Patients
N/A
Patients
N/A
Patients
N/A
Patients
N/A
Patients
10 m (FY, 2022)
Patients
22.8 m (FY, 2023)
Patients
N/A
Phase I Trials Products
Phase I Trials Products
N/A
Phase I Trials Products
N/A
Phase I Trials Products
N/A
Phase I Trials Products
N/A
Phase I Trials Products
20 (FY, 2020)
Phase I Trials Products
N/A
Phase I Trials Products
N/A
Phase I Trials Products
N/A
Phase I Trials Products
16 (FY, 2021)
Phase I Trials Products
N/A
Phase I Trials Products
N/A
Phase I Trials Products
N/A
Phase I Trials Products (Immunology)
Phase I Trials Products (Immunology)
1 (Oct, 2020)
Phase I Trials Products (Immunology)
N/A
Phase I Trials Products (Immunology)
N/A
Phase I Trials Products (Immunology)
N/A
Phase I Trials Products (Immunology)
N/A
Phase I Trials Products (Immunology)
6 (FY, 2021)
Phase I Trials Products (Immunology)
N/A
Phase I Trials Products (Immunology)
N/A
Phase I Trials Products (Immunology)
N/A
Phase I Trials Products (Immunology)
N/A
Phase I Trials Products (Immunology)
N/A
Phase I Trials Products (Immunology)
N/A
Phase I Trials Products (Oncology)
Phase I Trials Products (Oncology)
1 (FY, 2020)
Phase I Trials Products (Oncology)
7 (FY, 2019)
Phase I Trials Products (Oncology)
N/A
Phase I Trials Products (Oncology)
9 (FY, 2021)
Phase I Trials Products (Oncology)
N/A
Phase I Trials Products (Oncology)
20 (FY, 2021)
Phase I Trials Products (Oncology)
N/A
Phase I Trials Products (Oncology)
N/A
Phase I Trials Products (Oncology)
N/A
Phase I Trials Products (Oncology)
N/A
Phase I Trials Products (Oncology)
N/A
Phase I Trials Products (Oncology)
N/A
Phase II Trials Products
Phase II Trials Products
N/A
Phase II Trials Products
N/A
Phase II Trials Products
N/A
Phase II Trials Products
N/A
Phase II Trials Products
5 (FY, 2020)
Phase II Trials Products
N/A
Phase II Trials Products
N/A
Phase II Trials Products
N/A
Phase II Trials Products
6 (FY, 2021)
Phase II Trials Products
N/A
Phase II Trials Products
N/A
Phase II Trials Products
N/A
Phase II Trials Products (Immunology)
Phase II Trials Products (Immunology)
1 (Oct, 2020)
Phase II Trials Products (Immunology)
N/A
Phase II Trials Products (Immunology)
N/A
Phase II Trials Products (Immunology)
N/A
Phase II Trials Products (Immunology)
N/A
Phase II Trials Products (Immunology)
6 (FY, 2021)
Phase II Trials Products (Immunology)
N/A
Phase II Trials Products (Immunology)
N/A
Phase II Trials Products (Immunology)
N/A
Phase II Trials Products (Immunology)
N/A
Phase II Trials Products (Immunology)
N/A
Phase II Trials Products (Immunology)
N/A
Phase II Trials Products (Oncology)
Phase II Trials Products (Oncology)
1 (FY, 2020)
Phase II Trials Products (Oncology)
1 (FY, 2021)
Phase II Trials Products (Oncology)
N/A
Phase II Trials Products (Oncology)
12 (FY, 2021)
Phase II Trials Products (Oncology)
N/A
Phase II Trials Products (Oncology)
15 (FY, 2021)
Phase II Trials Products (Oncology)
N/A
Phase II Trials Products (Oncology)
N/A
Phase II Trials Products (Oncology)
N/A
Phase II Trials Products (Oncology)
N/A
Phase II Trials Products (Oncology)
N/A
Phase II Trials Products (Oncology)
N/A
Phase III Trials Products
Phase III Trials Products
N/A
Phase III Trials Products
9 (FY, 2021)
Phase III Trials Products
N/A
Phase III Trials Products
N/A
Phase III Trials Products
11 (FY, 2020)
Phase III Trials Products
N/A
Phase III Trials Products
N/A
Phase III Trials Products
N/A
Phase III Trials Products
11 (FY, 2021)
Phase III Trials Products
44 (FY, 2022)
Phase III Trials Products
N/A
Phase III Trials Products
N/A
Phase III Trials Products (Immunology)
Phase III Trials Products (Immunology)
1 (Oct, 2020)
Phase III Trials Products (Immunology)
N/A
Phase III Trials Products (Immunology)
N/A
Phase III Trials Products (Immunology)
N/A
Phase III Trials Products (Immunology)
N/A
Phase III Trials Products (Immunology)
3 (FY, 2021)
Phase III Trials Products (Immunology)
N/A
Phase III Trials Products (Immunology)
N/A
Phase III Trials Products (Immunology)
N/A
Phase III Trials Products (Immunology)
N/A
Phase III Trials Products (Immunology)
N/A
Phase III Trials Products (Immunology)
N/A
Phase III Trials Products (Oncology)
Phase III Trials Products (Oncology)
4 (Oct, 2020)
Phase III Trials Products (Oncology)
4 (FY, 2021)
Phase III Trials Products (Oncology)
N/A
Phase III Trials Products (Oncology)
N/A
Phase III Trials Products (Oncology)
N/A
Phase III Trials Products (Oncology)
7 (FY, 2021)
Phase III Trials Products (Oncology)
N/A
Phase III Trials Products (Oncology)
N/A
Phase III Trials Products (Oncology)
N/A
Phase III Trials Products (Oncology)
27 (FY, 2021)
Phase III Trials Products (Oncology)
N/A
Phase III Trials Products (Oncology)
N/A
Products
Products
N/A
Products
21 (FY, 2021)
Products
N/A
Products
N/A
Products
N/A
Products
N/A
Products
N/A
Products
300 k (FY, 2021)
Products
N/A
Products
N/A
Products
N/A
Products
N/A
Suppliers
Suppliers
N/A
Suppliers
N/A
Suppliers
N/A
Suppliers
68 k (FY, 2019)
Suppliers
N/A
Suppliers
N/A
Suppliers
N/A
Suppliers
N/A
Suppliers
37.5 k (FY, 2021)
Suppliers
N/A
Suppliers
N/A
Suppliers
N/A

Funding

Total funding raised
Total funding raised
N/A
Total funding raised
N/A
Total funding raised
$ 30m
Total funding raised
$ 310m
Total funding raised
N/A
Total funding raised
$ 15.5m
Total funding raised
N/A
Total funding raised
$ 121m
Total funding raised
N/A
Total funding raised
$ 6.5m
Total funding raised
$ 7.8b
Total funding raised
N/A
For sources of this data, please see the company profile

View Company Profiles

Gilead Sciences
HQ
Foster City, US
Employees
18,000↑ 6% increase

Gilead Sciences is a research-based biopharmaceutical company focused on the discovery, development, and commercialization of medicines.

View company
Immunomedics
HQ
Morris Plains, US

Immunomedics is a developer of monoclonal antibody-based products for the targeted treatment of cancer.

View company
Sanofi
HQ
Paris, FR
Employees
86,088↓ 6% decrease

Sanofi is a global healthcare company engaged in the research, development, manufacture, and marketing of therapeutic solutions.

View company
Amgen
HQ
Thousand Oaks, US
Employees
25,200

Amgen (formerly known as Applied Molecular Genetics) is a biotechnology company that discovers, develops, manufactures, and delivers human therapeutics.

View company